Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03033927

Predicting Effective Therapy in Pancreatic Cancer

The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Adenocarcinoma Pancreatic Diseases Pancreatic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment.
  • Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.
  • Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.
  • ECOG performance status 0-2.
  • A minimum age of 18 years old.

Exclusion criteria

  • Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
  • Known to be HIV positive on antiretroviral therapy
  • Prior organ allograft
  • Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures

Treatment and study plan

CTC isolocation and analysis

Diagnostic Test

Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.

Primary outcomes

  1. Progression Free Survival

    Time frame: 36 months

    in patients receiving frontline therapy predicted to be effective versus ineffective based on CTC PGx analysis

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Registry information

Official study title

Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response

Important dates

Study start
2017
Primary completion
2027
Study completion
2027
First posted
Jan 27, 2017
Registry last updated
Apr 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.